

# Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

NCT07071155

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Early Phase 1
<b>Sponsor</b>	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
<b>Enrollment</b>	18 participants

## Key Eligibility Criteria

---

### Inclusion (23)

- Patients of age 18 or older
- Has a diagnosis of MDS/MPN or CNL by WHO or ICC diagnostic criteria:
- Chronic myelomonocytic leukemia
- MDS/MPN with neutrophilia, previously known as atypical chronic myeloid leukemia
- Chronic neutrophilic leukemia
- ... and 18 more (see full listing online)

### Exclusion (26)

- Diagnosis of MDS/MPN with SF3B1 gene mutation and thrombocytosis (excluded due to unclear role of ACRV1 in the development of anemia)
- Peripheral blood or marrow (by immunohistochemistry) blast percentage  $\geq 10\%$
- Prior lack of response to MMB or hypomethylating agents.
- Known history of allergic reaction to momelotinib
- AST or ALT above 2.5 x ULN (above 5 X ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
- ... and 21 more (see full listing online)

## Locations (1 total)

---

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States